Bicycle Therapeutics (BCYC) Share-based Compensation (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Share-based Compensation data on file, last reported at $6.4 million in Q2 2026.

• Quarterly Share-based Compensation fell 32.13% year-over-year to $6.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.7 million (down 82.65% YoY) and the FY2025 annual result came in at $29.3 million, down 39.34% from the prior year.
• Share-based Compensation eased to $6.4 million in Q2 2026, from $6.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $10.3 million in Q4 2024 to a low of -$15.4 million in Q4 2025.
• A 5-year average of $6.8 million and a median of $8.5 million in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 166.89% — and 2025, when it slumped 249.14%.
• Tracing BCYC's Share-based Compensation over 5 years: stood at $5.5 million in 2022, then jumped by 41.01% to $7.8 million in 2023, then jumped by 32.27% to $10.3 million in 2024, then tumbled by 249.14% to -$15.4 million in 2025, then surged by 141.55% to $6.4 million in 2026.
• The last three Share-based Compensation figures came in at $6.4 million (Q2 2026), $6.9 million (Q1 2026), and -$15.4 million (Q4 2025), per Business Quant data.